Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash & Current Investments (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Cash & Current Investments for 5 consecutive years, with $245.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments fell 21.98% to $245.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $245.0 million through Dec 2025, down 21.98% year-over-year, with the annual reading at $245.0 million for FY2025, 21.98% down from the prior year.
  • Cash & Current Investments hit $245.0 million in Q4 2025 for ARS Pharmaceuticals, down from $288.2 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $374.2 million in Q1 2021 to a low of $60.1 million in Q4 2021.
  • Historically, Cash & Current Investments has averaged $257.2 million across 5 years, with a median of $255.9 million in 2022.
  • Biggest YoY gain for Cash & Current Investments was 356.82% in 2022; the steepest drop was 32.16% in 2022.
  • Year by year, Cash & Current Investments stood at $60.1 million in 2021, then surged by 356.82% to $274.4 million in 2022, then decreased by 16.77% to $228.4 million in 2023, then skyrocketed by 37.51% to $314.0 million in 2024, then fell by 21.98% to $245.0 million in 2025.
  • Business Quant data shows Cash & Current Investments for SPRY at $245.0 million in Q4 2025, $288.2 million in Q3 2025, and $240.1 million in Q2 2025.